Molecular Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Will pay $3 mil. in cash and $1.5 mil. in MBI common stock to a class of stock purchasers under a lawsuit settlement given preliminary approval by the U.S. District Court for the Southern District of California, the company reports. The suit, filed in November 1992, "claimed that the company, its directors, and certain of its officers misled investors as to the timing of and prospects for approval" of the company's Albunex echocardiography contrast agent, MBI notes. The company "denied all claims of wrongdoing and maintains this denial as part of the settlement agreement." The insurer for directors and officers will provide $800,000 of the settlement's cash payment. As a result of the pact, MBI will record a $3.7 mil. charge to earnings for its fourth fiscal quarter ended March 31
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.